Diet, weight loss, and cardiovascular disease prevention

被引:14
作者
George A. Bray
Donna H. Ryan
David W. Harsha
机构
[1] Pennington Biomedical Research Center,
关键词
Impaired Glucose Tolerance; Orlistat; Main Drug Interaction; Sibutramine; Cardiovascular Disease Prevention;
D O I
10.1007/s11936-003-0025-9
中图分类号
学科分类号
摘要
Body weight, like cholesterol and blood pressure, are continuous variables. Overweight results when energy intake as food exceeds energy expenditure from exercise for a considerable period of time. When body weight becomes sufficiently high, it poses a risk to cardiovascular and metabolic health. The types of treatments considered by the physician and discussed with a patient should be based on this risk-benefit assessment. The body mass is the basic measurement for this assessment, and should be part of the “vital signs” when a patient is first evaluated by the medical staff. When the body mass index (BMI) is below 25 kg/m2, there is little risk from the body weight, but because obesity is a “stigmatized” condition, many patients, particularly women, desire to lose weight even within the normal range. For this purpose, a high-quality diet like the Dietary Approaches to Stopping Hypertension (DASH) diet at a reduced-calorie intake would be our recommendation. When the BMI is above 25 kg/m2, patients deserve dietary advice, but in addition to a reduced-calorie DASH-like diet, this is a place to consider using “portion-control” strategies, such as the nutrition labels that manufacturers provide on canned and frozen foods to guide patients in reducing calorie intake. In overweight individuals at high risk (ie, those with a BMI above 30 kg/m2 or impaired glucose tolerance, hypertension, or the metabolic syndrome), the use of orlistat or sibutramine along with diet, exercise, lifestyle changes, and portion control should be considered. When the BMI is above 35 kg/m2, bariatric surgery should also be discussed as an option for the "at-risk" individual. Evidence reviewed here shows that modest weight losses of 5% to 10% can reduce the risk of conversion from impaired glucose tolerance to diabetes and can maintain lower blood pressure over extended periods. All of the approaches described above can produce weight losses of this magnitude.
引用
收藏
页码:259 / 269
页数:10
相关论文
共 79 条
[1]  
Flegal KM(2002)Prevalence and trends in obesity among US adults, 1999–2000 JAMA 288 1723-1727
[2]  
Carroll MD(1994)Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991 JAMA 272 205-211
[3]  
Ogden CL(2001)Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II Ann Intern Med 134 1-11
[4]  
Kuczmarski RJ(1999)Current and potential drugs for treatment of obesity Endocr Rev 20 805-875
[5]  
Flegal KM(1998)Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group Lancet 352 167-172
[6]  
Campbell SM(1999)Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial JAMA 281 235-242
[7]  
Stevens VJ(2000)Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group Obes Res 8 49-61
[8]  
Obarzanek E(2000)Orlistat in the long-term treatment of obesity in primary care settings Arch Fam Med 9 160-167
[9]  
Cook NR(1998)Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study Diabetes Care 21 1288-1294
[10]  
Bray GA(2000)Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults Arch Intern Med 160 1321-1326